Protein degraded. Disease targeted. Lives transformed.
January 2023
Forward-looking Statements and Intellectual Property
Forward-looking Statements
The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. These forward-looking statements include, but are not limited to, statements regarding the therapeutic potential of C4 Therapeutics, Inc.'s technology and products. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, as well as the fact that the product candidates that we are developing or may develop may not demonstrate success in clinical trials. Prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The forward-looking statements
included in this presentation are subject to a variety of risks and uncertainties, including those set forth in our most recent and future filings
with the Securities and Exchange Commission. Our actual results could vary significantly from those anticipated in this presentation, and our financial condition and results of operations could be materially adversely affected. C4 Therapeutics, Inc. undertakes no obligation to update or revise the information contained in this presentation, whether as a result of new information, future events or circumstances or otherwise.
Intellectual Property
C4 Therapeutics, Inc. owns various registered and unregistered trademarks and service marks in the U.S. and internationally, including, without limitation, C4 THERAPEUTICS, our housemark logo, the name of our TORPEDO platform, and the names of our BIDAC and MONODAC degrader products. All trademarks, service marks, or trade names referred to in this presentation that we do not own are the
property of their respective owners. Solely for convenience, the trademarks, service marks, and trade names in this presentation are
referred to without the symbols ®, SM and ™, but those references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights to.
© 2023 C4 Therapeutics, Inc. | 2 |
C4T is a Leader in Delivering on the Promise of Targeted Protein Degradation
Our Mission
To deliver on the promise
of targeted protein
degradation science to create a new generation of medicines that transform patients' lives
WORLD-CLASS DEGRADER PLATFORM
Demonstrated ability to design orally bioavailable, catalytically efficient degraders
that maximize the benefits of degradation
RIGOROUS TARGET SELECTION
Focus on targets with a clear degrader
rationale
BROAD DEGRADER APPROACH
Only company with both MonoDAC
and BiDAC degraders in the clinic
ROBUST CLINICAL PIPELINE
4 oncology degraders against targets of high unmet need
© 2023 C4 Therapeutics, Inc. | 3 |
Focused Research and Development Strategy to Create New Medicines that Transform Patients' Lives
Progress1.) Progressmultiplemultiple smallsmallmoleculeculeoral
oncologyoncologydegrader
prodegradersms ininthetheclinic
to improveclinic upon standard of care.
3 Programs currently in the clinic
1 Additional program to enter the clinic by end of 2023
Advance the next | Expand the |
wave of research | application of the |
targets for difficult-to- | TORPEDO platform |
drug and classically | through existing and |
undruggable targets | new collaboration |
partners |
Robust internal discovery pipeline including 7 new oncology research programs
© 2023 C4 Therapeutics, Inc. | 4 |
Achievements in 2022 Position C4T for Success in 2023
2022 | 2023 | ||
Progress multiple | ✓ Progressed lead clinical program, | ❑ Present Phase 1 dose escalation data | |
from the Phase 1/2 trials of CFT7455 and | |||
small molecule oral | CFT7455 | ||
CFT8634 | |||
oncology degraders | ✓ Initiated two new clinical trials, CFT8634 | ❑ | Advance earlier stage programs, CFT1946 |
in the clinic | and CFT1946 | ||
and CFT8919 | |||
Expand the | ✓ Presented new clinical and preclinical | ❑ | Validate capability to drug |
data across three oncology programs | |||
application of the | ✓ Unveiled diverse MonoDAC chemical | previously undruggable targets | |
TORPEDO platform | ❑ | Demonstrate viability of BiDAC approach | |
library | |||
Advance the next | ❑ Progress partnership strategy to maximize | ||
✓ Initiated research activities for seven new | therapeutic applications of TPD | ||
wave of research | ❑ | Continue to leverage research and | |
oncology targets | |||
targets | |||
discovery to develop the next wave of | |||
targets | |||
Two clinical readouts in 2023 position C4T for a transformative year
© 2023 C4 Therapeutics, Inc. | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
C4 Therapeutics Inc. published this content on 08 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 January 2023 12:08:11 UTC.